[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obstructive-hypertrophic-cardiomyopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obstructive-hypertrophic-cardiomyopathy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,71,94,116,136,156],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100476881","a-prospective-registry-study-to-assess-real-world-patient-characteristics-treatment-patterns-and-longitudinal-outcomes-in-patients-receiving-mavacamten-and-other-treatments-for-symptomatic-obstructive-hypertrophic-cardiomyopathy-obstructive-hcm-100476881",false,"NCT05489705","A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)","Deliver Insights in Hypertrophic Cardiomyopathy and Observational Outcomes in Real World: United States and European Prospective Registry Study","DISCOVER-HCM","Inclusion Criteria\n\n* ≥ 18 years of age at the time of informed consent.\n* Willing and able to provide written informed consent form (ICF) and any required privacy authorization prior to the initiation of study procedures (or in those situations where consent cannot be given by participants, consent provided by their legally acceptable representatives)\n\nUnited States Sub-Study\n\n* Diagnosis of obstructive HCM consistent with 2020 American Heart Association\u002FAmerican College of Cardiology (AHA\u002FACC) guidelines.\n\n  * Obstructive HCM is defined clinically by the presence of increased LV wall thickness ≥ 15 mm (or ≥ 13 mm with positive family history of HCM) in a nondilated ventricular chamber that is not solely explained by abnormal loading conditions (eg, another cardiac or systemic disease) and peak LVOT gradient of ≥ 30 mmHg at rest or with provocation.\n* Has documented LVEF of ≥ 55% recorded by echocardiography within the last 6 months.\n* Symptoms consistent with NYHA functional class II-IV.\n* Receiving beta blocker (BB)s, non-dihydropyridine calcium. channel blockers (nonDHP CCBs), disopyramide, and\u002For mavacamten (once available) as part of routine clinical care; or currently receiving no treatment due to intolerance or failure of prior treatment (eg, BBs, non-DHP CCBs, or disopyramide) for obstructive HCM.\n\nEuropean Sub-study\n\n* Diagnosis of obstructive HCM consistent with the most recent European Society of Cardiology (ESC) and American Heart Association\u002FAmerican College of Cardiology (AHA\u002FACC) guidelines\n* Documented LVEF of ≥55% recorded by TTE\n* Documented symptoms consistent with NYHA functional class II-III at enrollment or within 6 months prior to enrollment (if not available at enrollment).\n* As part of routine clinical care for obstructive HCM: receiving BBs, non-DHP CCBs, disopyramide; initiating mavacamten at enrollment; or currently receiving no treatment due to intolerance or failure of prior treatment (e.g., BBs, non-DHP CCBs, or disopyramide).\n\nExclusion Criteria\n\n* Known phenocopy disease (e.g., Fabry disease, amyloidosis) or LV hypertrophy associated with hypertension.\n* Documentation of any fixed obstruction of the outflow tract such as aortic valve stenosis or replacement.\n* Prior treatment of obstructive HCM with invasive septal reduction (surgical myectomy or percutaneous alcohol septal ablation \\[ASA\\]) within 6 months prior to enrollment; participants with an unsuccessful myectomy or percutaneous ASA performed \\> 6 months prior to enrollment may be enrolled.\n* Naïve to treatment for obstructive HCM (ie, never treated with BBs, nonDHP CCBs, or disopyramide).\n\nUnited States Sub-Study\n\n* Receiving an investigational therapeutic agent for obstructive HCM (eg, myosin-inhibitors other than mavacamten) in an interventional clinical trial at participant enrollment.\n* Previously or currently enrolled in a long-term safety extension study of mavacamten (eg, EXPLORER-HCM \\[ClinicalTrials.gov, NCT03470545\\], MAVA-LTE \\[NCT03723655\\], PIONEER-OLE \\[NCT03496168\\], VALORHCM \\[NCT04349072\\], or MAVERICK \\[NCT03442764\\])\n\nEuropean Sub-study\n\n* Receiving an investigational therapeutic agent or any cardiac myosin inhibitor and\u002For modulators for obstructive HCM at patient enrolment\n* Previously or currently enrolled in other HCM registry studies (e.g., TORCH, REMY, EU-PASS)\n* Previously or currently enrolled in a study of mavacamten (e.g., EXPLORER-HCM \\[ClinicalTrials.gov, NCT03470545\\], MAVA-LTE \\[NCT03723655\\], PIONEER-OLE \\[NCT03496168\\], VALOR-HCM \\[NCT04349072\\], MAVERICK \\[NCT03442764\\], or MEMENTO \\[NCT2264899\\])\n* Previously treated with mavacamten","ALL","18 Years",{"count":20,"type":21},1700,"ESTIMATED","5 Years","OBSERVATIONAL","This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are receiving mavacamten, receiving other treatment for obstructive HCM, or not receiving treatment for obstructive HCM due to intolerance or failure of prior treatment.\n\nUnited States Sub-Study: The purpose of this study is to evaluate the safety of mavacamten in patients with symptomatic obstructive HCM in the real-world setting.\n\nEurope Sub-Study: The purpose of this study is to evaluate the effectiveness and safety of mavacamten in patients with symptomatic obstructive HCM in the real-world setting.",[26],"Obstructive Hypertrophic Cardiomyopathy",[28,29,30,31,32],"Obstructive hypertrophic cardiomyopathy","Obstructive HCM (oHCM)","Mavacamten","Heart failure","oHCM","RECRUITING","2026-06-11",{"date":36,"type":37},"2026-06-12","ACTUAL",{"date":39,"type":37},"2022-08-16",{"date":41,"type":21},"2029-08-17",{"name":43,"class":44},"Bristol-Myers Squibb","INDUSTRY",99,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100594632","phase-3-a-phase-iii-trial-of-hrs-1893-in-patients-with-obstructive-hypertrophic-cardiomyopathy-100594632","NCT07021976","A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy","A Multicentre, Randomized, Double-blind, Placebo-parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of HRS-1893 Tablets in the Treatment of Obstructive Hypertrophic Cardiomyopathy","Inclusion Criteria:\n\n1. Age 18-85 years old, gender unlimited.\n2. BMI\\\u003C35 kg\u002Fm2.\n3. The diagnosis was obstructive hypertrophic cardiomyopathy.\n4. Laboratory determination of echocardiography showed that Rest LVOT-G≥50 mmHg, or Rest LVOT-G≥30 mmHg and LVOT-G≥50 mmHg after Valsalva action.\n5. Echocardiographic laboratory tests showed LVEF≥60%.\n6. NYHA classification: Grade II - III.\n7. Understand the study procedure and sign the informed consent in person, willing to strictly follow the clinical study protocol to complete the study.\n\nExclusion Criteria:\n\n1. Known or suspected invasive, genetic or storage diseases (e.g. Noonan syndrome, Fabre's disease, amyloidosis) that cause cardiac hypertrophy (similar to oHCM).\n2. Had a history of severe valvular heart disease.\n3. Abnormal laboratory test results during screening, or any other clinically significant abnormal screening laboratory values, which are determined by the researcher to be unsuitable for inclusion.\n4. Other circumstances where the researchers consider the subjects unsuitable to participate in this trial, such as physical or mental illnesses or conditions that may increase the risk of the trial, affect the subjects' compliance with the protocol, or affect the subjects' completion of the trial.","85 Years",{"count":55,"type":21},216,"INTERVENTIONAL",[58],"PHASE3","The study is being conducted to evaluate the efficacy and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy.",[26],"2025-08-19",{"date":63,"type":37},"2025-08-20",{"date":65,"type":37},"2025-08-11",{"date":67,"type":21},"2026-11",{"name":69,"class":44},"Shandong Suncadia Medicine Co., Ltd.",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":56,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":89,"leadSponsor":91,"locationsCount":4},"100581896","efficacy-of-mavacamten-combined-with-radiofrequency-ablation-in-patients-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-100581896","NCT06856265","Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy","Inclusion Criteria:\n\n1. At least 18 years old at screening.\n2. Body weight was greater than 45 kg at screening.\n3. Diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) consistent with current American College of Cardiology Foundation\u002FAmerican Heart Association, European Society of Cardiology, and Chinese Society of Cardiology guidelines, ie, satisfy criteria below (criteria to be documented by the echocardiography core laboratory): A. Had unexplained left ventricular (LV) hypertrophy with nondilated ventricular chambers in the absence of other cardiac (eg, hypertension, aortic stenosis) or systemic disease and with maximal LV wall thickness ≥15 mm (or ≥13 mm with positive family history of hypertrophic cardiomyopathy), as determined by core laboratory interpretation, and B. Had left ventricular outflow tract (LVOT) peak gradient ≥50 mm Hg during screening as assessed by echocardiography at rest or after Valsalva maneuver (confirmed by echocardiography core laboratory interpretation).\n4. Had documented LV ejection fraction (LVEF) ≥55% by echocardiography core laboratory read of screening TTE at rest.\n5. Had a valid measurement of Valsalva LVOT peak gradient at screening as determined by echocardiography core laboratory.\n6. Had New York Heart Association (NYHA) class II or III symptoms at screening.\n7. Had documented oxygen saturation at rest ≥90% at screening.\n8. Study participants were able to understand and comply with the study procedures, understand the risks involved in the study, and provided written informed consent according to national, local, and institutional guidelines before the first study-specific procedure.\n\nExclusion Criteria:\n\n* 1\\) Participated in a clinical trial in which the participant received any investigational drug (or was currently using an investigational device) within 30 days prior to screening, or at least 5 times the respective elimination half-life (if known), whichever was longer.\n\n  2\\) Known infiltrative or storage disorder causing cardiac hypertrophy that mimics oHCM, such as Fabry disease, amyloidosis, or Noonan syndrome with LV hypertrophy. 3) Had a history of syncope within 6 months prior to screening or sustained ventricular tachyarrhythmia with exercise within 6 months prior to screening.\n\n  4\\) Had a history of resuscitated sudden cardiac arrest (at any time) or known history of appropriate implantable cardioverter-defibrillator (ICD) discharge for life-threatening ventricular arrhythmia within 6 months prior to screening.\n\n  5\\) Had paroxysmal, intermittent atrial fibrillation with atrial fibrillation present per the investigator's evaluation of the participant's electrocardiogram (ECG) at the time of screening.\n\n  6\\) Had persistent or permanent atrial fibrillation not on anticoagulation for at least 4 weeks prior to screening and\u002For not adequately rate-controlled within 6 months prior to screening (note: participants with persistent or permanent atrial fibrillation who were anticoagulated and adequately rate-controlled were allowed).\n\n  7\\) Previously participated in a clinical study with mavacamten. 8) Hypersensitivity to any of the components of the mavacamten formulation. 9) Current treatment (within 14 days prior to screening) or planned treatment during the study with disopyramide, cibenzoline, or ranolazine. 10) Current treatment (within 14 days prior to screening) or planned treatment during the double blinded treatment with a combination of beta-blockers and verapamil or a combination of beta blockers and diltiazem.\n\n  11\\) For individuals on beta-blockers, verapamil, or diltiazem, any dose adjustment of that medication within14 days prior to screening or any anticipated change in treatment regimen using these medications during the treatment.\n\n  12\\) Had been successfully treated with invasive septal reduction (surgical myectomy or percutaneous alcohol septal ablation \\[ASA\\]) within 6 months prior to screening or planned to have either of these treatments during the study (note: individuals with an unsuccessful myectomy or percutaneous ASA procedure performed \\>6 months prior to screening were enrolled if study eligibility criteria for LVOT gradient criteria were met).\n\n  13\\) ICD placement within 2 months prior to screening or planned ICD placement during the study.\n\n  14\\) Had QTcF \\>500 msec when QRS interval \\\u003C120 msec or QTcF \\>520 msec when QRS ≥120 msec or any other ECG abnormality considered by the investigator to pose a risk to participant safety (eg, second-degree atrioventricular block type II).\n\n  15\\) Had documented obstructive coronary artery disease (\\>70% stenosis in 1 or more epicardial coronary arteries) or history of myocardial infarction.\n\n  16\\) Had known moderate or severe (as per investigator's judgment) aortic valve stenosis, constrictive pericarditis, or clinically significant congenital heart disease at screening.\n\n  17\\) Had any acute or serious comorbid condition (eg, major infection or hematologic, renal, metabolic, gastrointestinal, or endocrine dysfunction) that, in the judgment of the investigator, could lead to premature termination of study participation or interfere with the measurement or interpretation of the efficacy and safety assessments in the study.\n\n  18\\) Unable to comply with the study requirements, including the number of required visits to the clinical site.\n\n  19\\) Pregnant or lactating female.",{"count":78,"type":21},40,[80],"NA","This study aims to evaluate the efficacy and safety of Mavacamten combined with radiofrequency ablation compared to Mavacamten alone in patients with symptomatic obstructive hypertrophic cardiomyopathy (HOCM).\n\nParticipants were randomized into two groups:",[26,30,83],"Radiofrequency Ablation","NOT_YET_RECRUITING","2025-02-26",{"date":87,"type":37},"2025-03-04",{"date":85,"type":21},{"date":90,"type":21},"2025-12-01",{"name":92,"class":93},"Shanghai Chest Hospital","OTHER",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":104,"conditions":105,"keywords":106,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":70},"100558439","real-world-patient-reported-outcomes-among-patients-treated-with-camzyos-100558439","NCT06551129","Real-world Patient Reported Outcomes Among Patients Treated With Camzyos","Real-World Camzyos Patient Reported OutcoMes Through PAtient SurveyS in Hypertrophic CardioMyopathy (COMPASS-HCM): A Prospective Longitudinal Study","COMPASS-HCM","Inclusion Criteria:\n\n* Participants ≥18 years of age.\n* Participants who are prescribed mavacamten for obstructive hypertrophic cardiomyopathy\n* Provided informed consent to participate in the study\n\nExclusion Criteria:\n\n* Previously or currently enrolled in clinical trials for any cardiac myosin inhibitors\n* Treated for \\>7 days with mavacamten by the day of completing the baseline survey\n* Enrolled in any clinical trials at the time of or within the six-month period prior to the screening\n* Had heart attack requiring coronary artery bypass grafting within the three-month period prior to the screening\n* Had stroke or transient ischemic attack within the six-month period prior to the screening\n* Had moderate-to-severe lung disease which impacted the ability to perform daily activities of living and ability to breathe\n* Had major lung (thoracic) or heart (cardiac) surgery within the six-month period prior to the screening\n* Scheduled for a major surgery for the next three months, such as joint surgeries including hip replacement, abdominal surgeries, lung surgeries, heart surgeries, eye surgeries, brain surgeries, and any other major surgeries that require general anesthesia and at least an overnight hospital stay\n* Hospitalized requiring an overnight stay at the time of or within the two-week period prior to the screening",{"count":103,"type":21},118,"This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.",[26],[107],"Obstructive Hypertrophic cardiomyopathy","2024-11-06",{"date":110,"type":37},"2024-11-07",{"date":112,"type":37},"2024-05-10",{"date":114,"type":21},"2027-06-30",{"name":43,"class":44},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":123,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},"100527353","a-study-to-assess-the-safety-of-mavacamten-in-korean-patients-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-100527353","NCT06146660","A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy","CAMZYOS® (Mavacamten) Post-Marketing Surveillance in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)","Inclusion Criteria:\n\n* Adult participants 19 years of age or older\n* Participants who receive mavacamten according to the approved product label\n* Participants who sign the informed consent form\n\nExclusion Criteria:\n\n* Participants who are prescribed mavacamten for therapeutic indications not approved in Korea\n* Participants for whom mavacamten is contraindicated as clarified in Korean prescribing information approved by the Ministry of Food and Drug Safety","19 Years",{"count":125,"type":21},600,"The purpose of this observational post-marketing surveillance study is to assess the real-world safety of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult participants in Korea. Participants who will receive at least 1 dose of mavacamten will be enrolled.",[26],"2024-11-05",{"date":108,"type":37},{"date":131,"type":37},"2024-07-24",{"date":133,"type":21},"2026-11-30",{"name":43,"class":44},2,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":70},"100517872","effect-of-mavacamten-treatment-on-coronary-flow-reserve-in-ohcm-100517872","NCT06023186","Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM","Coronary Flow Reserve in oHCM Patients Before and After 12 Months of Standard-of-care Mavacamten Treatment as Assessed by PET\u002FCT","MavaPET","Inclusion Criteria:\n\n1. Willingness and ability to provide written informed consent\n2. Willingness and ability to comply with scheduled visits and study procedures\n3. Male or female, aged 18-85 years\n4. Diagnosed with obstructive hypertrophic cardiomyopathy according to presence of a left ventricular wall thickness of ≥15 mm that is otherwise unexplained by abnormal loading conditions (e.g., hypertension, valvular, congenital disease) or infiltrative cardiomyopathies. Unexplained left ventricular wall thickness of ≥13 mm is sufficient for diagnosis in relatives of individuals with hypertrophic cardiomyopathy or those who are genotype positive.\n5. Has been prescribed mavacamten consistent with US Prescribing Information\n6. Ability and intention to adhere to oral mavacamten therapy as prescribed by treating physician for the duration of study participation\n7. For females of reproductive potential: negative pregnancy test at screening\u002Fbaseline and 12 month visits.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation\n2. Known hypersensitivity to components of mavacamten or regadenoson\n3. Prior treatment with mavacamten or aficamten\n\n11\\. Over weight limit for imaging gantry. 12. To minimize the risk of participants undergoing PET\u002FCT with inadequate image quality, participants with left ventricular systolic dysfunction or lung disease will be excluded.",{"count":145,"type":21},20,"The goal of this observational study is to measure the effect of mavacamten treatment on blood flow in the heart muscle (myocardium) in patients with obstructive hypertrophic cardiomyopathy. The main question it aims to answer is:\n\n• Does mavacamten treatment improve blood flow in the heart muscle?\n\nParticipants will take mavacamten at the direction of their treating physician. Participants will complete 2 myocardial Positron Emission Tomography and Computed Tomography (PET-CT) scans. The first scan will be completed before participants start taking mavacamten. The scan will be repeated after 12 months of mavacamten treatment.",[26],"2024-11-04",{"date":108,"type":37},{"date":151,"type":37},"2023-11-03",{"date":153,"type":21},"2026-09-30",{"name":155,"class":93},"Michael Ayers",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":56,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":70},"100544373","feasibility-study-of-the-dragonfire-for-hypertrophic-obstructive-cardiomyopathy-100544373","NCT06368037","Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy","To Evaluate the Safety and Feasibility of the DragonFire Transcatheter Radiofrequency Myocardial Ablation System","Inclusion Criteria:\n\n* (1) Age ≥18 years; (2) Diagnosis of obstructive hypertrophic cardiomyopathy, with a peak left ventricular outflow tract gradient (LVOTG) ≥50mmHg at rest or with provocation; (3) Significant clinical symptoms including fatigue, dyspnea, exertional angina, syncope, severely affecting quality of life, and either inadequate response to standardized drug therapy or inability to tolerate drug side effects, with anatomical suitability for alcohol septal ablation and myocardial radiofrequency ablation system and use of catheter-based myocardial radiofrequency ablation needle and its guidance system; (4) NYHA functional class ≥III, or NYHA functional class II patients with one of the following: ① Severe progressive pulmonary arterial hypertension caused by outflow obstruction or resulting mitral regurgitation; ② Atrial fibrillation with associated left atrial enlargement; ③ Exercise treadmill testing indicating reduced cardiac function due to outflow obstruction; (5) Judged by the local clinical trial institution research team as high surgical risk (recommended reference criteria: advanced age or severe comorbidities, or presence of other surgical high-risk factors, such as: ≥2 moderate to severe frailty indicators or potential surgical obstacles, or ≥1 major organ dysfunction that cannot be improved after surgery, or other surgical high-risk factors judged by the cardiac team), or patients who, after being fully informed of the risks and benefits of surgery by the research team, still refuse to undergo surgery; (6) Expected survival of more than 12 months and able to adhere to the follow-up plan; (7) The subject has been informed of the nature of the study, understands the purpose of the clinical trial, voluntarily participates, and signs the informed consent form.\n\nExclusion Criteria:\n\n* (1) Non-obstructive hypertrophic cardiomyopathy and end-stage hypertrophic cardiomyopathy; (2) Interventricular septum thickness \\\u003C15mm; (3) Significant diffuse thickening of the interventricular septum; (4) 5-year sudden cardiac death risk score (SCDI) ≥10%, or history of cardiac sudden death (SCD) events, or ventricular fibrillation, or sustained ventricular tachycardia leading to loss of consciousness, or ventricular arrhythmias causing hemodynamic instability in patients without an implanted ICD; (5) Left ventricular ejection fraction \\\u003C50%; (6) Transthoracic echocardiography suggesting the presence of intracavitary masses, thrombi, or vegetations; (7) History of surgical septal myectomy, alcohol ablation, or other interventricular septal ablation procedures; (8) Any cardiovascular intervention within 30 days or cardiac surgery within 6 months; (9) Concurrent presence of other cardiac diseases requiring surgical treatment, such as severe mitral valve disease, multi-vessel coronary artery disease, etc.; (10) Acute heart failure (defined as acute hemodynamic abnormalities occurring on the basis of primary cardiac or non-cardiac diseases, resulting in a clinical syndrome primarily characterized by acute pulmonary edema, cardiogenic shock, and elevated plasma levels of B-type natriuretic peptide) or end-stage heart failure (defined as resting heart failure, intractable pulmonary edema, or pleural or pericardial effusion despite intensified anti-heart failure treatment); (11) Preoperative presence of right bundle branch block, left bundle branch block, or atrioventricular block requiring permanent pacemaker implantation, or previously implanted permanent cardiac pacemaker; (12) Significant coronary artery disease or critical lesions requiring revascularization due to coronary perfusion-demand mismatch (QFR or FFR \\\u003C0.8), or those experiencing ischemic events within 30 days; (13) Vascular diseases affecting access for investigational devices, such as aortic aneurysm, severe aortic stenosis, severe aortic arch or aortic valve calcification, or tortuosity or stenosis of the iliac artery; (14) Inability to determine target septal branch or balloon not being fixable in the septal branch, or cardiac anatomy unsuitable for alcohol septal ablation; (15) Hemodynamic instability, defined as systolic blood pressure \\\u003C90mmHg without the use of afterload-reducing drugs accompanied by symptoms of hypoperfusion, or cardiogenic shock; or requiring vasopressor therapy; or requiring intra-aortic balloon counterpulsation; or other hemodynamic support devices; (16) History of acute peptic ulcer or gastrointestinal bleeding within 3 months; (17) Severe chronic obstructive pulmonary disease (COPD) (requiring continuous home oxygen therapy or long-term use of corticosteroids); (18) History of ischemic cerebrovascular accident (within the past 30 days), or severe carotid artery stenosis (ultrasound showing unilateral carotid artery stenosis \\>70%), or carotid artery stent implantation within 30 days, or history of hemorrhagic cerebrovascular accident (within 6 months); (19) Bleeding disorders or coagulation disorders, or contraindications to antithrombotic therapy; (20) Renal insufficiency (serum creatinine \\>2.0mg\u002FdL or 177 µmol\u002FL or eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2 or undergoing dialysis treatment; (21) Active infection requiring concurrent antibiotic therapy (if temporary, patients must discontinue antibiotic use for at least 14 days before enrollment); (22) Planned pregnancy, pregnant, or lactating females; (23) Contraindications to transesophageal echocardiography or general anesthesia; (24) Expected lifespan less than 12 months, or disease that would make evaluation of treatment difficult (such as cancer, severe metabolic diseases, psychiatric disorders, etc.) unable to complete the study as required, or poor compliance as judged by the researcher; (25) Currently participating in another experimental drug or medical device clinical study with unfinished primary endpoints or clinical studies that may interfere with the endpoints of this study; (26) Other circumstances judged by the researcher as unsuitable for participation in this study.",{"count":164,"type":21},10,[80],"This study is a prospective, single-center, single-group design exploratory clinical research. No control group is set, and only subjects meeting the indications of the study device are treated. After patients sign informed consent, they are screened, and those meeting the inclusion criteria are enrolled. The treatment involves using myocardial radiofrequency ablation system and catheter-based myocardial radiofrequency ablation needle and its guidance system for treating obstructive hypertrophic cardiomyopathy. All subjects are followed up before discharge, and at 30 days, 3 months, 6 months, and 12 months postoperatively.",[26],"2024-04-11",{"date":170,"type":37},"2024-04-16",{"date":172,"type":21},"2024-08",{"date":174,"type":21},"2026-06",{"name":176,"class":44},"Hangzhou Valgen Medtech Co., Ltd"]